EA201792539A1 - Peptide-Oligonucleotide Conjugates - Google Patents

Peptide-Oligonucleotide Conjugates

Info

Publication number
EA201792539A1
EA201792539A1 EA201792539A EA201792539A EA201792539A1 EA 201792539 A1 EA201792539 A1 EA 201792539A1 EA 201792539 A EA201792539 A EA 201792539A EA 201792539 A EA201792539 A EA 201792539A EA 201792539 A1 EA201792539 A1 EA 201792539A1
Authority
EA
Eurasian Patent Office
Prior art keywords
peptide
oligonucleotide conjugates
oligonucleotides
peptides
subject
Prior art date
Application number
EA201792539A
Other languages
Russian (ru)
Other versions
EA039716B1 (en
Inventor
Гуннар Дж. Хансон
Мин Чжоу
Original Assignee
Сарепта Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сарепта Терапьютикс, Инк. filed Critical Сарепта Терапьютикс, Инк.
Priority claimed from PCT/US2016/033276 external-priority patent/WO2016187425A1/en
Publication of EA201792539A1 publication Critical patent/EA201792539A1/en
Publication of EA039716B1 publication Critical patent/EA039716B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

В данном документе представлены олигонуклеотиды, пептиды и пептид-олигонуклеотидные конъюгаты. Также в данном документе представлены способы лечения мышечного заболевания, вирусной инфекции или бактериальной инфекции у субъекта, нуждающегося в этом, включающие введение субъекту олигонуклеотидов, пептидов и пептид-олигонуклеотидных конъюгатов, описанных в данном документе.This document presents oligonucleotides, peptides and peptide-oligonucleotide conjugates. Also presented herein are methods for treating muscle disease, viral infection or bacterial infection in a subject in need thereof, including administering to the subject the oligonucleotides, peptides and peptide-oligonucleotide conjugates described herein.

EA201792539A 2016-05-17 2016-05-19 Peptide-oligonucleotide conjugates EA039716B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662337536P 2016-05-17 2016-05-17
PCT/US2016/033276 WO2016187425A1 (en) 2015-05-19 2016-05-19 Peptide oligonucleotide conjugates

Publications (2)

Publication Number Publication Date
EA201792539A1 true EA201792539A1 (en) 2018-11-30
EA039716B1 EA039716B1 (en) 2022-03-03

Family

ID=81077470

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201792539A EA039716B1 (en) 2016-05-17 2016-05-19 Peptide-oligonucleotide conjugates

Country Status (1)

Country Link
EA (1) EA039716B1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6559279B1 (en) * 2000-09-08 2003-05-06 Isis Pharmaceuticals, Inc. Process for preparing peptide derivatized oligomeric compounds
US20110269665A1 (en) * 2009-06-26 2011-11-03 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
ES2832531T3 (en) * 2011-11-30 2021-06-10 Sarepta Therapeutics Inc Oligonucleotides for the treatment of repeat expansion diseases

Also Published As

Publication number Publication date
EA039716B1 (en) 2022-03-03

Similar Documents

Publication Publication Date Title
NZ737757A (en) Peptide oligonucleotide conjugates
JOP20200192A1 (en) Anti-tigit antibodies
EA201891186A1 (en) ANTIBODIES, NEUTRALIZING THE VIRUS OF HUMAN IMMUNODEFICIENCY
MX2019012233A (en) Anti-sirp alpha antibodies.
EA201700181A1 (en) COMPOSITIONS OF ADENOSINDEMINASE-2 (ADA-2), THEIR OPTIONS AND METHODS OF USE
WO2017030823A3 (en) Anti-tigit antibodies
BR112017026061A2 (en) compound, use of a compound, and method of treating a viral infection
EA201591758A1 (en) Sub-ADAMTS13 INTRODUCTION
WO2015054678A3 (en) Human papilloma virus therapeutic vaccine
EA201891419A1 (en) Peptide-Oligonucleotide Conjugates
EA201692111A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING DANIRYXIN FOR TREATING INFECTIOUS DISEASES
EA201890347A1 (en) ANTIBODIES AND RESEARCH FOR DETECTION CD37
MX2020002802A (en) Heavy chain antibodies binding to ectoenzymes.
MX2018014129A (en) Pharmaceutical composition comprising eteplirsen.
MX2021006865A (en) Anti-alpha-synuclein antibodies and uses thereof.
EA202091112A1 (en) SOCRYSTALS, PHARMACEUTICAL COMPOSITIONS BASED ON THEIR BASED AND METHODS OF TREATMENT FOR THEIR APPLICATION
EA201792539A1 (en) Peptide-Oligonucleotide Conjugates
EA201791442A1 (en) METHODS OF TREATMENT OF HEMATOLOGICAL DISTURBANCES, SOLID TUMORS OR INFECTIOUS DISEASES WITH THE USE OF NATURAL CELL-CALLERS
EA201892675A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING ETHEPLIRSEN
EA202091619A3 (en) ANTIBODIES AGAINST TIGIT
RU2016144119A (en) A method for the treatment of dogs with brucellosis
TH1701000860A (en) Antibody Antibody-TIGIT
EA201691835A1 (en) ALLASTERIC MODULATORS OF CAPSIDE PROTEIN OF HEPATITIS B